Anixa Biosciences (NASDAQ:ANIX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Wednesday morning,Benzinga reports. They currently have a $10.00 price target on the stock.

ANIX has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.50.

Anixa Biosciences Stock Up 1.5%

Shares of NASDAQ ANIX opened at $2.73 on Wednesday. The stock has a market capitalization of $91.54 million, a price-to-earnings ratio of -8.27 and a beta of 0.57. The stock’s fifty day simple moving average is $2.83 and its 200 day simple moving average is $3.49. Anixa Biosciences has a 52-week low of $2.38 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Monday, March 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. As a group, analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Transactions at Anixa Biosciences

In related news, Director Arnold M. Baskies purchased 10,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director directly owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC acquired a new stake in Anixa Biosciences during the 2nd quarter worth $33,000. Cetera Investment Advisers acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $35,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Anixa Biosciences by 2,000.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. acquired a new stake in shares of Anixa Biosciences in the 2nd quarter valued at about $37,000. Finally, Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at about $38,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.